TY - JOUR AU - Burchert, Andreas PY - 2021/03/01 Y2 - 2024/03/28 TI - Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia JF - Haematologica JA - haematol VL - 106 IS - 3 SE - Review Articles DO - 10.3324/haematol.2019.240747 UR - https://haematologica.org/article/view/haematol.2019.240747 SP - 664-670 AB - FLT3-ITD is a constitutively activated variant of the FLT3 tyrosine kinase receptor. Its expression in acute myeloid leukemia (AML) is associated with a poor prognosis. Due to this, the development of tyrosine kinase inhibitors (TKI) blocking FLT3-ITD became a rational therapeutic concept. This review describes key milestones in the clinical development of different FLT3-specific TKI with a particular focus on FLT3-TKI maintenance therapy in remission after allogeneic hematopoietic stem cell transplantation (HCT). Recent evidence from randomized trials using sorafenib in FLT3-ITD mutated AML provided a proof of concept that targeted post-HCT maintenance therapy could become a new treatment paradigm in AML. ER -